{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:06:08Z","timestamp":1790193968329,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":75,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_847","type":"book-chapter","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:28Z","timestamp":1790191948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors"],"prefix":"10.1007","author":[{"given":"Anna","family":"Solini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tric\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"847_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M, Investigators C (2025) Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 393:533\u2013543. https:\/\/doi.org\/10.1056\/NEJMoa2410659","journal-title":"N Engl J Med"},{"key":"847_CR2","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.jacc.2020.09.616","volume":"76","author":"R Aggarwal","year":"2020","unstructured":"Aggarwal R, Lu K, Chiu N, Bakris GL, Bhatt DL (2020) U.S. prevalence of individuals with diabetes and chronic kidney disease indicated for SGLT-2 inhibitor therapy. J Am Coll Cardiol 76:2907\u20132910. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.616","journal-title":"J Am Coll Cardiol"},{"key":"847_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.007875","volume":"14","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Chiu N, Bhatt DL (2021) Generalizability of DAPA-CKD to the United States. Circ Cardiovasc Qual Outcomes 14:e007875. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.007875","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"847_CR4","doi-asserted-by":"publisher","unstructured":"An Y, Zhang H (2025) SGLT-2 inhibitors: a deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction. Am J Nephrol:1\u201313. https:\/\/doi.org\/10.1159\/000546079","DOI":"10.1159\/000546079"},{"key":"847_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021a) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"847_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner\u2013La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M (2021b) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"847_CR7","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"M Bajaj","year":"2026","unstructured":"Bajaj M, McCoy RG, Balapattabi K, Bannuru RR, Bellini NJ, Bennett AK, Beverly EA, Briggs Early K, ChallaSivaKanaka S, Echouffo-Tcheugui JB, Everett BM, Garg R, Laffel LM, Lal R, Matfin G, Neumiller JJ, Pandya N, Pekas EJ, Peters AL, Pilla SJ, Romeo GR, Rosas SE, Segal AR, Szmuilowicz ED, ElSayed NA (2026) 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142026. Diabetes Care 49:S246\u2013S260. https:\/\/doi.org\/10.2337\/dc26-S011","journal-title":"Diabetes Care"},{"key":"847_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"847_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"847_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY (2025) Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol 24:177. https:\/\/doi.org\/10.1186\/s12933-025-02737-1","journal-title":"Cardiovasc Diabetol"},{"key":"847_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","volume":"64","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Shih WJ, Frederich R, Maldonado M, Pong A, Cannon CP, Investigators VC (2021) Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 64:1256\u20131267. https:\/\/doi.org\/10.1007\/s00125-021-05407-5","journal-title":"Diabetologia"},{"key":"847_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ndt\/gfaf064","volume":"40","author":"MH Chuang","year":"2025","unstructured":"Chuang MH, Wang HY, Kan WC, Chien CC, Jiang MY, Huang YT, Wu VC, Chen JY (2025) Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol Dial Transplant 40:1897\u20131905. https:\/\/doi.org\/10.1093\/ndt\/gfaf064","journal-title":"Nephrol Dial Transplant"},{"key":"847_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00125-025-06565-6","volume":"69","author":"JMT Colombijn","year":"2026","unstructured":"Colombijn JMT, de Leijer JF, Visseren FLJ, Verhaar MC, van Raalte DH, Sattar N, Vernooij RWM, van Sloten TT (2026) Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia 69:36\u201349. https:\/\/doi.org\/10.1007\/s00125-025-06565-6","journal-title":"Diabetologia"},{"key":"847_CR14","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00125-024-06251-z","volume":"67","author":"GP Fadini","year":"2024","unstructured":"Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A (2024a) Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia 67:2585\u20132597. https:\/\/doi.org\/10.1007\/s00125-024-06251-z","journal-title":"Diabetologia"},{"key":"847_CR15","doi-asserted-by":"publisher","unstructured":"Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A, Baldassarre M, Consoli A, Morganet S, Zugaro A, Baroni MG, Andreozzi F, Gatti A, Gatti A, De Riu S, Del Buono A, Aldigeri R, Bonadonna R, Cas AD, Vazzana A, Antonini M, Moretti V, Volsi PL, Cesare M, Zanette G, Carletti S, D'Angelo P, Leto G, Leonetti F, D'Onofrio L, Maddaloni E, Buzzetti R, Frontoni S, Cavallo G, Morano S, Filardi T, Capece U, Giaccari A, Bossi AC, Meregalli G, Querci F, Gaglio A, Resi V, Orsi E, Fazion S, Franzetti IG, Berra C, Manfrini S, Garrapa G, Lucarelli G, Riccialdelli L, Tortato E, Zavattaro M, Aimaretti G, Cavalot F, Beccuti G, Broglio F, Fattor B, Cazzetta G, Lamacchia O, Rauseo A, De Cosmo S, Cau R, Ghiani M, Di Benedetto A, Di Pino A, Piro S, Purrello F, Frittitta L, Milluzzo A, Russo G (2024b) Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur 38. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100847","DOI":"10.1016\/j.lanepe.2024.100847"},{"key":"847_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","volume":"16","author":"B Fernandez-Fernandez","year":"2023","unstructured":"Fernandez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A (2023) EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16:1187\u20131198. https:\/\/doi.org\/10.1093\/ckj\/sfad082","journal-title":"Clin Kidney J"},{"key":"847_CR17","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1111\/dom.15111","volume":"25","author":"AK Forbes","year":"2023","unstructured":"Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, de Lusignan S, Swift PA (2023) Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab 25:2310\u20132330. https:\/\/doi.org\/10.1111\/dom.15111","journal-title":"Diabetes Obes Metab"},{"key":"847_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/00325481.2024.2426442","volume":"136","author":"S Geng","year":"2024","unstructured":"Geng S, Li Y, Ge J, Liu Y, Li Q, Chen X, Zhu Y, Guo X, Yuan H, Wang X, Jiang H (2024) Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study. Postgrad Med 136:855\u2013863. https:\/\/doi.org\/10.1080\/00325481.2024.2426442","journal-title":"Postgrad Med"},{"key":"847_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","volume":"392","author":"WG Herrington","year":"2025","unstructured":"Group E-KC, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, Group E-KC (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 392:777\u2013787. https:\/\/doi.org\/10.1056\/NEJMoa2409183","journal-title":"N Engl J Med"},{"key":"847_CR20","doi-asserted-by":"publisher","unstructured":"Hanouneh M, Le D, Jaar BG, Tamargo C, Cervantes CE (2024) Real-life experience on the effect of SGLT2 inhibitors vs. finerenone vs combination on albuminuria in chronic kidney disease. Diagnostics (Basel) 14. https:\/\/doi.org\/10.3390\/diagnostics14131357","DOI":"10.3390\/diagnostics14131357"},{"key":"847_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/cjn.02480221","volume":"16","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Cherney DZI (2021) Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 16:1278\u20131280. https:\/\/doi.org\/10.2215\/cjn.02480221","journal-title":"Clin J Am Soc Nephrol"},{"key":"847_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin F-J, Wang C-Y, Wittbrodt E, Fenici P, Kosiborod M (2020a) Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 8:27\u201335. https:\/\/doi.org\/10.1016\/s2213-8587(19)30384-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"847_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj\u00f6str\u00f6m CD, Toto RD, Langkilde A-M, Wheeler DC (2020b) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"847_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"847_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02150-0","volume":"23","author":"PT Htoo","year":"2024","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Deruaz-Luyet A, Paik JM, Patorno E (2024) Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol 23:57. https:\/\/doi.org\/10.1186\/s12933-024-02150-0","journal-title":"Cardiovasc Diabetol"},{"key":"847_CR26","doi-asserted-by":"publisher","unstructured":"Hunsuwan S, Boongird S, Ingsathit A, Ponthongmak W, Unwanatham N, McKay GJ, Attia J, Thakkinstian A (2025) Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease. Sci Rep 15. https:\/\/doi.org\/10.1038\/s41598-025-86172-y","DOI":"10.1038\/s41598-025-86172-y"},{"key":"847_CR27","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1111\/dom.14799","volume":"24","author":"I Idris","year":"2022","unstructured":"Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K (2022) Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: an observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab 24:2138\u20132147. https:\/\/doi.org\/10.1111\/dom.14799","journal-title":"Diabetes Obes Metab"},{"key":"847_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, Investigators CS (2020) Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol 31:1128\u20131139. https:\/\/doi.org\/10.1681\/ASN.2019111168","journal-title":"J Am Soc Nephrol"},{"key":"847_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjostrand M, McMurray JJV (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143:298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050391","journal-title":"Circulation"},{"key":"847_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101418","volume":"49","author":"A Karasik","year":"2023","unstructured":"Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nystrom T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Deruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Nunez J, Europe E, Asia Study G (2023) Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab 49:101418. https:\/\/doi.org\/10.1016\/j.diabet.2022.101418","journal-title":"Diabetes Metab"},{"key":"847_CR31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10157-024-02532-4","volume":"28","author":"R Kawano","year":"2024","unstructured":"Kawano R, Haze T, Fujiwara A, Haruna A, Ozawa M, Kobayashi Y, Saka S, Hirawa N, Tamura K (2024) Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip. Clin Exp Nephrol 28:1282\u20131289. https:\/\/doi.org\/10.1007\/s10157-024-02532-4","journal-title":"Clin Exp Nephrol"},{"key":"847_CR32","doi-asserted-by":"publisher","unstructured":"Kitaoka K, Yano Y, Nagasu H, Kanegae H, Chishima N, Akiyama H, Tamura K, Kashihara N (2024) Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan chronic kidney disease database ex. BMJ Open Diabetes Res Care 12. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004115","DOI":"10.1136\/bmjdrc-2024-004115"},{"key":"847_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/dom.14239","volume":"23","author":"ES Koh","year":"2020","unstructured":"Koh ES, Han K, Nam YS, Wittbrodt ET, Fenici P, Kosiborod MN, Heerspink HJL, Yoo SJ, Kwon HS (2020) Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Diabetes Obes Metab 23:455\u2013466. https:\/\/doi.org\/10.1111\/dom.14239","journal-title":"Diabetes Obes Metab"},{"key":"847_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/circulationaha.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, J\u00f8rgensen ME, Thuresson M, Arya N, Bodeg\u00e5rd J, Hammar N, Fenici P (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Circulation 136:249\u2013259. https:\/\/doi.org\/10.1161\/circulationaha.117.029190","journal-title":"Circulation"},{"key":"847_CR35","doi-asserted-by":"publisher","unstructured":"Lin F-J, Wang C-C, Hsu C-N, Yang C-Y, Wang C-Y, Ou H-T (2021) Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study. Cardiovasc Diabetol 20. https:\/\/doi.org\/10.1186\/s12933-021-01396-2","DOI":"10.1186\/s12933-021-01396-2"},{"key":"847_CR36","doi-asserted-by":"publisher","unstructured":"Lin DS-H, Lo H-Y, Huang K-C, Lin T-T, Huang C-Y, Lee J-K, Lin L-Y (2026) Sex differences in cardiovascular and renal outcomes with sodium\u2013glucose cotransporter 2 inhibitors: a meta-analysis of randomized controlled trials. Eur J Med Res 31. https:\/\/doi.org\/10.1186\/s40001-026-03849-4","DOI":"10.1186\/s40001-026-03849-4"},{"key":"847_CR37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","volume":"15","author":"AYL Liu","year":"2022","unstructured":"Liu AYL, Low S, Yeoh E, Lim EK, Renaud CJ, Teoh STY, Tan GFL, Chai CC, Liu B, Subramaniam T, Sum CF, Lim SC (2022) A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J 15:1403\u20131414. https:\/\/doi.org\/10.1093\/ckj\/sfac044","journal-title":"Clin Kidney J"},{"key":"847_CR38","doi-asserted-by":"publisher","unstructured":"Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P (2022) SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res 183. https:\/\/doi.org\/10.1016\/j.phrs.2022.106396","DOI":"10.1016\/j.phrs.2022.106396"},{"key":"847_CR39","doi-asserted-by":"publisher","unstructured":"Madero M, Chertow GM, Mark PB (2024) SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med 6. https:\/\/doi.org\/10.1016\/j.xkme.2024.100851","DOI":"10.1016\/j.xkme.2024.100851"},{"key":"847_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","volume":"8","author":"FR Mc Causland","year":"2023","unstructured":"Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol 8:56\u201365. https:\/\/doi.org\/10.1001\/jamacardio.2022.4210","journal-title":"JAMA Cardiol"},{"key":"847_CR41","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","volume":"39","author":"P McEwan","year":"2024","unstructured":"McEwan P, Gabb PD, Davis JA, Garcia Sanchez JJ, Sj\u00f6str\u00f6m CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL (2024) The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant 39:2040\u20132047. https:\/\/doi.org\/10.1093\/ndt\/gfae106","journal-title":"Nephrol Dial Transplant"},{"key":"847_CR42","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde A-M (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"847_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","volume":"143","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, Mann JFE, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Heerspink HJL, Committees D-CT, Investigators (2021) Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation 143:438\u2013448. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051675","journal-title":"Circulation"},{"key":"847_CR44","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7:606\u2013617. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"847_CR45","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, Shigematsu T, Sofue T, Ito T, Okada H, Nakashima N, Kataoka H, Ohe K, Okada M, Itano S, Nishiyama A, Kanda E, Ueki K, Kashihara N (2021) Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in Real-world clinical practice: the Japan chronic kidney disease database. Diabetes Care 44:2542\u20132551. https:\/\/doi.org\/10.2337\/dc21-1081","journal-title":"Diabetes Care"},{"key":"847_CR46","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/dom.15623","volume":"26","author":"A Nakhleh","year":"2024","unstructured":"Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, Yarden A, Khazim K, Shehadeh N, Melzer Cohen C (2024) Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes Obes Metab 26:3058\u20133067. https:\/\/doi.org\/10.1111\/dom.15623","journal-title":"Diabetes Obes Metab"},{"key":"847_CR47","doi-asserted-by":"publisher","unstructured":"Nakhleh A, Khazim K, Shehadeh N (2025) Real-world effectiveness of finerenone added to SGLT2 inhibitor and GLP-1 receptor agonist therapy in individuals with type 2 diabetes and chronic kidney disease. J Clin Med 14. https:\/\/doi.org\/10.3390\/jcm14228209","DOI":"10.3390\/jcm14228209"},{"key":"847_CR48","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"847_CR49","doi-asserted-by":"publisher","unstructured":"Neuen BL, Fletcher RA, Anker SD, Bhatt DL, Butler J, Cherney DZI, Docherty KF, Inzucchi SE, Jardine MJ, Mahaffey KW, McCausland FR, McGuire DK, McMurray JJV, Neal B, Packer M, Patel SM, Perkovic V, Sabatine MS, Sardell RJ, Solomon SD, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Haynes R, Staplin N, Herrington WG, Heerspink HJL, Consortium SIM-AC-RT (2025) SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.20834","DOI":"10.1001\/jama.2025.20834"},{"issue":"Suppl 5","key":"847_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/dom.15696","volume":"26","author":"T Nystrom","year":"2024","unstructured":"Nystrom T (2024) Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk. Diabetes Obes Metab 26(Suppl 5):35\u201357. https:\/\/doi.org\/10.1111\/dom.15696","journal-title":"Diabetes Obes Metab"},{"key":"847_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/dom.14870","volume":"25","author":"T Nystrom","year":"2023","unstructured":"Nystrom T, Toresson Grip E, Gunnarsson J, Casajust P, Karlsdotter K, Skogsberg J, Ustyugova A, Group ES (2023) Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: real world evidence from the Nordic EMPRISE study. Diabetes Obes Metab 25:261\u2013271. https:\/\/doi.org\/10.1111\/dom.14870","journal-title":"Diabetes Obes Metab"},{"key":"847_CR52","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F (2020a) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"847_CR53","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, Investigators EM-RT (2020b) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"847_CR54","doi-asserted-by":"publisher","unstructured":"Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, Gudbj\u00f6rnsdottir S, Hveem K, Jonasson C, Svanstr\u00f6m H, Ueda P (2020) Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ. https:\/\/doi.org\/10.1136\/bmj.m1186","DOI":"10.1136\/bmj.m1186"},{"key":"847_CR55","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.14593","volume":"24","author":"E Patorno","year":"2022","unstructured":"Patorno E, Pawar A, Wexler DJ, Glynn RJ, Bessette LG, Paik JM, Najafzadeh M, Brodovicz KG, Deruaz-Luyet A, Schneeweiss S (2022) Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab 24:442\u2013454. https:\/\/doi.org\/10.1111\/dom.14593","journal-title":"Diabetes Obes Metab"},{"key":"847_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B (2018) Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 6:691\u2013704. https:\/\/doi.org\/10.1016\/S2213-8587(18)30141-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"847_CR57","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019a) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"847_CR58","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, Investigators CT (2019b) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"847_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12933-021-01323-5","volume":"20","author":"J Real","year":"2021","unstructured":"Real J, Vlacho B, Ortega E, Valles JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J (2021) Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol 20:139. https:\/\/doi.org\/10.1186\/s12933-021-01323-5","journal-title":"Cardiovasc Diabetol"},{"key":"847_CR60","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R, Fidelio DKD, Investigators F-D (2022a) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45:2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"key":"847_CR61","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, Sadusky T, Tandon N, Tuttle KR, Wanner C, Wilkens KG, Zoungas S, de Boer IH (2022b) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102:S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"847_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ (2025) Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab 51:101594. https:\/\/doi.org\/10.1016\/j.diabet.2024.101594","journal-title":"Diabetes Metab"},{"key":"847_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.183","volume":"4","author":"Y Seino","year":"2021","unstructured":"Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, W HHS, group EEAs (2021) Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: results from the EMPRISE East Asia study. Endocrinol Diabetes Metab 4:e00183. https:\/\/doi.org\/10.1002\/edm2.183","journal-title":"Endocrinol Diabetes Metab"},{"key":"847_CR64","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","volume":"24","author":"A Shokravi","year":"2025","unstructured":"Shokravi A, Seth J, Mancini GBJ (2025) Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol 24:370. https:\/\/doi.org\/10.1186\/s12933-025-02900-8","journal-title":"Cardiovasc Diabetol"},{"key":"847_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ 385:e078242. https:\/\/doi.org\/10.1136\/bmj-2023-078242","journal-title":"BMJ"},{"key":"847_CR66","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, Committees DT, Investigators (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"847_CR67","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.0000000000000414","volume":"19","author":"VS Sridhar","year":"2024","unstructured":"Sridhar VS, Bhatt DL, Odutayo A, Szarek M, Davies MJ, Banks P, Pitt B, Steg PG, Cherney DZI (2024) Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: a secondary analysis of the SCORED trial. Clin J Am Soc Nephrol 19:557\u2013564. https:\/\/doi.org\/10.2215\/CJN.0000000000000414","journal-title":"Clin J Am Soc Nephrol"},{"key":"847_CR68","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazanc\u0131o\u011flu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M, Shroff R, Tangri N, Thanachayanont T, Ulasi I, Wong G, Yang C-W, Zhang L, Levin A (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"847_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ndt\/gfae158","volume":"40","author":"Y Suzuki","year":"2025","unstructured":"Suzuki Y, Kaneko H, Okada A, Komuro J, Ko T, Fujiu K, Takeda N, Morita H, Nishiyama A, Ieda M, Node K, Yasunaga H, Nangaku M, Komuro I (2025) Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes. Nephrol Dial Transplant 40:495\u2013504. https:\/\/doi.org\/10.1093\/ndt\/gfae158","journal-title":"Nephrol Dial Transplant"},{"key":"847_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"847_CR71","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, Investigators E-RO (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"847_CR72","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"847_CR73","doi-asserted-by":"publisher","unstructured":"Xiao X, Ji S, Zheng T, Wang T, Jiang D, Liu F (2024) Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China. Front Pharmacol 15. https:\/\/doi.org\/10.3389\/fphar.2024.1468435","DOI":"10.3389\/fphar.2024.1468435"},{"key":"847_CR74","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, Al-Aly Z (2020) Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43:2859\u20132869. https:\/\/doi.org\/10.2337\/dc20-1890","journal-title":"Diabetes Care"},{"key":"847_CR75","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:29Z","timestamp":1790191949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/164_2026_847","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"24 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}